Key facts
- This page summarizes Jeff E. Knight's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2024, 17:31.
Jeff E. Knight - 26 Jun 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Issuer symbol
- CRNX
- Report date
- 26 Jun 2024
- Net transaction value
- -$42,427
- Form type
- 4
- Accepted by SEC
- 28 Jun 2024, 17:31:49 UTC
- Previous filing
- 26 Mar 2024
- Next filing
- 17 Jul 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- Marc Wilson, as attorney-in-fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Jeff E. Knight filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 28 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Mar 2024.
- Current net transaction value: -$42,427.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Sale
- Transaction value
- $42,427
- Shares
- -956
- Change %
- -1.8%
- Price
- $44.38
- Shares after
- 52,580
- Date
- 26 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
Includes 956 shares acquired under the Issuer's Employee Stock Purchase Plan.